var data={"title":"Rabies virus vaccine: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Rabies virus vaccine: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6891?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=rabies-virus-vaccine-drug-information\" class=\"drug drug_general\">see &quot;Rabies virus vaccine: Drug information&quot;</a> and <a href=\"topic.htm?path=rabies-virus-vaccine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Rabies virus vaccine: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216827\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Imovax Rabies;</li>\n      <li>RabAvert</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216828\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Imovax Rabies;</li>\n      <li>RabAvert</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1061757\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Vaccine</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Vaccine, Inactivated Virus</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16144579\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Postexposure prophylaxis:</b> All postexposure treatment should begin with immediate cleansing of the wound with soap and water (for ~15 minutes); immunization should begin as soon as possible after exposure. Administer with rabies immune globulin (RIG). On presented dosing, Day 0 is the first day vaccine administered.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Immunocompetent:</i> 4-dose regimen: IM: 1 mL/dose for 4 doses on days 0, 3, 7, and 14 postexposure (ACIP [Rupprecht 2010])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Immunocompromised: </i>5-dose regimen: IM: 1 mL/dose for 5 doses on days 0, 3, 7, 14, and 28 postexposure (ACIP [Rupprecht 2010])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1061750\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=rabies-virus-vaccine-drug-information\" class=\"drug drug_general\">see &quot;Rabies virus vaccine: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Preexposure vaccination:</b> Infants, Children, and Adolescents: IM: 1 mL/dose for 3 doses, on days 0, 7, and 21 or 28. <b>Note:</b> Prolonging the interval between doses does not interfere with immunity achieved after the concluding dose of the basic series.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Booster vaccination (for persons with continuous or frequent risk of infection)</i>: Infants, Children, and Adolescents: IM: 1 mL/dose based on antibody titers</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Postexposure vaccination:</b> Infants, Children, and Adolescents: All postexposure treatment should begin with immediate cleansing of the wound with soap and water (for ~15 minutes); immunization should begin as soon as possible after exposure. On presented dosing, Day 0 is the first day vaccine administered.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Persons <b>not</b> previously immunized: Administer with rabies immune globulin (RIG):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Immunocompetent: </i>4-dose regimen: IM: 1 mL/dose for 4 doses on days 0, 3, 7, and 14 postexposure (ACIP [Rupprecht 2010])</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Immunocompromised:</i> 5-dose regimen: IM: 1 mL/dose for 5 doses on days 0, 3, 7, 14, and 28 postexposure (ACIP [Rupprecht 2010])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Persons who have previously received vaccine (either previous postexposure prophylaxis or preexposure series of vaccination) or have a previously documented rabies antibody titer considered adequate: IM: 1 mL/dose on days 0 and 3 postexposure; do not administer RIG</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Preexposure vaccination:</b> IM: A total of 3 doses, 1 mL each, on days 0, 7, and 21 or 28. <b>Note:</b> Prolonging the interval between doses does not interfere with immunity achieved after the concluding dose of the basic series.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Booster vaccination (for persons with continuous or frequent risk of infection):</i> IM: 1 mL based on antibody titers</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Postexposure vaccination:</b> All postexposure treatment should begin with immediate cleansing of the wound with soap and water.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Persons <b>not</b> previously immunized as above:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Immunocompetent:</i> IM: 4 doses (1 mL each) on days 0, 3, 7, and 14 postexposure (ACIP [Rupprecht 2010])</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Immunocompromised:</i> IM: 5 doses (1 mL each) on days 0, 3, 7, 14, and 28 postexposure (ACIP [Rupprecht 2010])</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <b>Note:</b> In addition, patients should receive rabies immune globulin with the first dose (day 0).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Persons who have previously received postexposure prophylaxis with rabies vaccine, received a recommended IM preexposure series of rabies vaccine or have a previously documented rabies antibody titer considered adequate: IM: Two doses (1 mL each) on days 0 and 3 postexposure; do not administer rabies immune globulin</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216810\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Injectable, Intramuscular [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Imovax Rabies: 2.5 units/mL (1 ea) [contains albumin human, neomycin sulfate]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension Reconstituted, Intramuscular: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">RabAvert: 2.5 units (1 ea) [contains albumin human, chicken protein, edetate disodium, gelatin (bovine), neomycin]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216796\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50015659\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span><p>(For additional information <a href=\"topic.htm?path=rabies-virus-vaccine-drug-information\" class=\"drug drug_general\">see &quot;Rabies virus vaccine: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Imovax Rabies is grown in human diploid cell culture.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RabAvert is grown in purified chick embryo cell culture (PCEC).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25734192\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">In the US, the CDC-approved Vaccine Information Statement (VIS) is available at <a target=\"_blank\" href=\"http://www.cdc.gov/vaccines/hcp/vis/vis-statements/rabies.html&amp;token=x0GjZnbwEt1zI9GtF4rROTyNLGBExBWkh+dxZUuK9R8iAlL05ClMvIota3ITK9d8wmkBb9GDsjNlb0Srz20Pug==&amp;TOPIC_ID=12950\" target=\"_blank\">http://www.cdc.gov/vaccines/hcp/vis/vis-statements/rabies.html</a>.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1061760\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IM: Not for IV or SubQ administration; reconstitute immediately before administration; administer injections in the deltoid muscle; for infants and small children the outer aspect of the thigh may be used. Do not administer to the gluteal region; may decrease efficacy. Do not administer in same syringe as RIG. Do not mix with other vaccines or injections. To prevent syncope related injuries, adolescents and adults should be vaccinated while seated or lying down (ACIP [Kroger 2017]). US law requires that the date of administration, the vaccine manufacturer, lot number of vaccine, and the administering person's name, title, and address be entered into the patient's permanent medical record.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">For patients at risk of hemorrhage following intramuscular injection, the vaccine should be administered intramuscularly if, in the opinion of the physician familiar with the patient's bleeding risk, the vaccine can be administered by this route with reasonable safety. If the patient receives antihemophilia or other similar therapy, intramuscular vaccination can be scheduled shortly after such therapy is administered. A fine needle (23-gauge or smaller) should be used for the vaccination and firm pressure on the site (without rubbing) for at least 2 minutes. The patient should be instructed concerning the risk of hematoma from the injection. Patients on anticoagulant therapy should be considered to have the same bleeding risks and treated as those with clotting factor disorders (ACIP [Kroger 2017]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216825\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Prior to reconstitution, store under refrigeration at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); do not freeze. RabAvert should be protected from light. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1061759\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Preexposure and postexposure vaccination against rabies (FDA approved in all ages). Factors to consider include: Species of biting animal, circumstances of biting incident (provoked vs unprovoked bite), type of exposure to rabies infection (bite vs nonbite), vaccination status of biting animal, and presence of rabies in the region. Refer to local/state health department and CDC for more information. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">The Advisory Committee on Immunization Practices (ACIP) recommends a primary course of prophylactic immunization (preexposure vaccination) for the following (ACIP [Manning 2008]): </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Persons with continuous risk of infection, including rabies research laboratory and biologics production workers</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Persons with frequent risk of infection, including rabies diagnostic laboratory workers, cavers, veterinarians and their staff, and animal control and wildlife workers in areas where rabies is enzootic; persons who frequently handle bats </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Persons with infrequent risk of infection, including veterinarians and animal control staff working with terrestrial animals in areas where rabies infection is rare, veterinary students, and travelers visiting areas where rabies is enzootic and immediate access to medical care and biologicals is limited </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">The ACIP recommends the use of postexposure vaccination for a particular person be assessed by the severity and likelihood versus the actual risk of acquiring rabies. Consideration should include the type of exposure, epidemiology of rabies in the area, species of the animal, circumstances of the incident, and the availability of the exposing animal for observation or rabies testing. Postexposure vaccination is used in both previously vaccinated and previously unvaccinated individuals (ACIP [Manning 2008]; ACIP [Rupprecht 2010]). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216842\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Cardiovascular toxicity, edema, palpitations, swelling of injected limb (extensive)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Chills, dizziness, encephalitis, fatigue, Guillain-Barre syndrome, headache, malaise, meningitis, neuropathy, paralysis (may be transient; includes neuroparalysis), paresthesia (transient), retrobulbar neuritis, seizure, vertigo</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Injection site pruritus, pruritus, urticaria (including urticaria pigmentosa)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Hot flash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain, diarrhea, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Adenopathy, lymphadenopathy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Anaphylaxis, hypersensitivity reaction, serum sickness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Erythema at injection site, hematoma at injection site, pain at injection site, swelling at injection site</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia, arthritis (one joint), limb pain, multiple sclerosis, myalgia, myelitis, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Visual disturbance</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Bronchospasm, dyspnea, wheezing</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever &gt;38&deg;C (100&deg;F)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216817\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Preexposure prophylaxis: Life-threatening hypersensitivity to rabies vaccine or any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Postexposure prophylaxis: There are no contraindications listed within the FDA-approved manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216800\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylactoid/hypersensitivity reactions: Immediate treatment (including epinephrine 1 mg/mL) for anaphylactoid and/or hypersensitivity reactions should be available during vaccine use (ACIP [Kroger 2017]). Once postexposure prophylaxis has begun, administration should generally not be interrupted or discontinued due to local or mild adverse events. Continuation of vaccination following severe systemic reactions should consider the persons risk of developing rabies. Report serious reactions to the State Health Department or the manufacturer/distributor.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immune complex-like reactions (serum sickness): An immune complex reaction is possible to 2 to 21 days following booster doses of HDCV. Symptoms may include arthralgia, arthritis, angioedema, fever, generalized urticaria, malaise, nausea, and vomiting.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neurologic reactions: Rare cases of Guillain-Barre syndrome (transient neuroparalytic illnesses that resolves without sequelae in 12 weeks, potentially fatal encephalitis, meningitis, transient paralysis, myelitis, retrobulbar neuritis, and multiple sclerosis) have been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Syncope: Syncope has been reported with use of injectable vaccines and may result in serious secondary injury (eg, skull fracture, cerebral hemorrhage); typically reported in adolescents and young adults and within 15 minutes after vaccination. Procedures should be in place to avoid injuries from falling and to restore cerebral perfusion if syncope occurs (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bleeding disorders: Use with caution in patients with a history of bleeding disorders (including thrombocytopenia); bleeding/hematoma may occur from IM administration; if the patient receives antihemophilia or other similar therapy, IM injection can be scheduled shortly after such therapy is administered (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Altered immunocompetence: Consider deferring immunization during periods of severe immunosuppression (eg, patients receiving chemo/radiation therapy [including high-dose corticosteroids]); may have a reduced response to vaccination. Withhold nonessential immunosuppressive agents during postexposure prophylaxis; if possible postpone pre-exposure prophylaxis until the immunocompromising condition is resolved. Persons with altered immunocompetence should receive the five-dose postexposure vaccine regimen. In general, household and close contacts of persons with altered immunocompetence may receive all age appropriate vaccines (ACIP [Kroger 2017]; IDSA [Rubin 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Apnea has occurred following intramuscular vaccine administration in premature infants; consider clinical status implications. In general, preterm infants should be vaccinated at the same chronological age as full-term infants (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anticoagulant therapy: Use with caution in patients receiving anticoagulant therapy; bleeding/hematoma may occur from IM administration (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Vaccines: In order to maximize vaccination rates, the ACIP recommends simultaneous administration (ie, &gt;1 vaccine on the same day at different anatomic sites) of all age-appropriate vaccines (live or inactivated) for which a person is eligible at a single clinic visit, unless contraindications exist. The ACIP prefers each dose of a specific vaccine in a series come from the same manufacturer when possible (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Albumin: Products may contain albumin and therefore carry a remote risk of transmitting Creutzfeldt-Jakob or other viral diseases.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Imovax Rabies: Contains neomycin.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; RabAvert: Contains amphotericin B, bovine gelatin, chicken protein, chlortetracycline, and neomycin.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Antipyretics: Antipyretics have not been shown to prevent febrile seizures; antipyretics may be used to treat fever or discomfort following vaccination (ACIP [Kroger 2017]). One study reported that routine prophylactic administration of acetaminophen prior to vaccination to prevent fever decreased the immune response of some vaccines; the clinical significance of this reduction in immune response has not been established (Prymula 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Rabies vaccine should not be used in persons with a confirmed diagnosis of rabies; use after the onset of symptoms may be detrimental (ACIP [Manning 2008]). Postexposure vaccination may begin regardless of the length of time from documented or likely exposure, as long as clinical signs of rabies are not present; however, it is ideal to start the treatment as soon as possible.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Effective immunity: Vaccination may not result in effective immunity in all patients. Response depends upon multiple factors (eg, type of vaccine, age of patient) and may be improved by administering the vaccine at the recommended dose, route, and interval. Vaccines may not be effective if administered during periods of altered immune competence (ACIP [Kroger 2017]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299976\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216804\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12950&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Belimumab: May diminish the therapeutic effect of Vaccines (Inactivated). Management: Patients should receive inactivated vaccines prior to initiation of belimumab therapy whenever possible, due to the risk for an impaired response to the vaccine during belimumab therapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloroquine: May diminish the therapeutic effect of Rabies Vaccine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: May diminish the therapeutic effect of Vaccines (Inactivated). Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting fingolimod. If vaccinated during fingolimod therapy, revaccinate 2 to 3 months after fingolimod discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immunosuppressants: May diminish the therapeutic effect of Vaccines (Inactivated). Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<b> Exceptions: </b>Cytarabine (Liposomal).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rabies Immune Globulin (Human): May diminish the therapeutic effect of Rabies Vaccine. Management: Do not administer additional or repeated doses of rabies immune globulin once rabies vaccine has been administered. The rabies immune globulin should also not be administered in the same site as the vaccine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Venetoclax: May diminish the therapeutic effect of Vaccines (Inactivated).<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216806\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216820\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. Pregnancy is not a contraindication to postexposure prophylaxis. Pre-exposure prophylaxis during pregnancy may also be considered if risk of rabies is great. Inactivated vaccines have not been shown to cause increased risks to the fetus (ACIP [Kroger 2017]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1061756\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Observe for syncope for 15 minutes following administration (ACIP [Kroger 2017]). If seizure-like activity associated with syncope occurs, maintain patient in supine or Trendelenburg position to reestablish adequate cerebral perfusion.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Antibody response to vaccination is not recommended for otherwise healthy persons who complete the preexposure or postexposure regimen. Serologic testing to determine if the antibody titer is at an acceptable level is required for the following persons (booster vaccination recommended if titer is below the acceptable level) (ACIP [Manning 2008]):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Persons with continuous risk of infection: Serologic testing every 6 months</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Persons with frequent risk of infection: Serologic testing every 2 years</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Persons who are immunocompromised: Serologic testing after completion of preexposure or postexposure prophylaxis series</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46502582\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">Adequate adaptive immune response: Antibody titers of 0.5 international units/mL (WHO 2014) or complete virus neutralization at a 1:5 serum dilution by the rapid fluorescent focus inhibition test (RFFIT) (ACIP [Manning 2008])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216799\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Rabies vaccine is an inactivated virus vaccine which promotes immunity by inducing an active immune response. The production of specific antibodies requires about 7-10 days to develop. Rabies immune globulin or antirabies serum, equine (ARS) is given in conjunction with rabies vaccine to provide immune protection until an antibody response can occur.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216816\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: IM: Rabies antibody: ~7 to 10 days </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Peak effect: ~30 to 60 days </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: &ge;1 year</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5687023\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Injection</b> (Imovax Rabies Intramuscular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5 units/mL (1): $407.26</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038796\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Abhayrab (TH);</li>\n      <li>Berrab P (HK);</li>\n      <li>Imovax Rabbia (IT);</li>\n      <li>Imovax Rabia (UY);</li>\n      <li>Imovax Rabies (PL);</li>\n      <li>Lyssavac N Berna (HK, MY, PH);</li>\n      <li>Rabies MIRV Vaccine (NZ);</li>\n      <li>Rabies-Imovax (FI, NO, SE);</li>\n      <li>Rabiesvax (PH);</li>\n      <li>Rabipur (AT, AU, BG, CZ, DE, DK, ES, FR, GB, HR, ID, IN, LU, NL, PH, PT, RO, SE, SG, TH);</li>\n      <li>Rabivax (BD);</li>\n      <li>Rabix-VC (BD);</li>\n      <li>Speeda (PH, TH);</li>\n      <li>Verorab (BG, CN, CO, CR, DO, GT, HN, KR, LK, MY, PA, PE, SV, UA, VN)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Imovax (rabies vaccine) [prescribing information]. Swiftwater, PA: Sanofi Pasteur, Inc; April 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kroger AT, Duchin J, Vazquez M. General Best Practice Guidelines for Immunization. Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP). Availabe at <a href=\"https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf\" target=\"_blank\">https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf</a>. Accessed on 04.28.2017.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rabies-virus-vaccine-pediatric-drug-information/abstract-text/21617632/pubmed\" target=\"_blank\" id=\"21617632\">21617632</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Manning SE, Rupprecht CE, Fishbein D, et al, &quot;Human Rabies Prevention--United States, 2008: Recommendations of the Advisory Committee on Immunization Practices,&quot; <i>MMWR Recomm Rep</i>, 2008, 57(RR-3):1-28.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rabies-virus-vaccine-pediatric-drug-information/abstract-text/18496505/pubmed\" target=\"_blank\" id=\"18496505\">18496505</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Prymula R, Siegrist CA, Chlibek R, et al, &quot;Effect of Prophylactic Paracetamol Administration at Time of Vaccination on Febrile Reactions and Antibody Responses in Children: Two Open-Label, Randomised Controlled Trials,&quot; <i>Lancet</i>, 2009, 374(9698):1339-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rabies-virus-vaccine-pediatric-drug-information/abstract-text/19837254/pubmed\" target=\"_blank\" id=\"19837254\">19837254</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    RabAvert (rabies vaccine) [prescribing information]. Emeryville, CA: Novartis Vaccines and Diagnostics, Inc; December 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rupprecht CE, Briggs D, Brown CM, et al, &quot;Use of a Reduced (4-Dose) Vaccine Schedule for Postexposure Prophylaxis to Prevent Human Rabies: Recommendations of the Advisory Committee on Immunization Practices,&quot; <i>MMWR Recomm Rep</i>, 2010, 59(RR-2):1-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rabies-virus-vaccine-pediatric-drug-information/abstract-text/20300058/pubmed\" target=\"_blank\" id=\"20300058\">20300058</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO). Rabies pre and post exposure prophylaxis in humans, 2014. Available at http://www.who.int/rabies/PEP_Prophylaxis_guideline_15_12_2014.pdf?ua=1</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12950 Version 119.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F216827\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F216828\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1061757\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F16144579\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1061750\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F216810\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F216796\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F50015659\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F25734192\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1061760\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F216825\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1061759\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F216842\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F216817\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F216800\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299976\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F216804\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F216806\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F216820\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1061756\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F46502582\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F216799\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F216816\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F5687023\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038796\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12950|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=rabies-virus-vaccine-drug-information\" class=\"drug drug_general\">Rabies virus vaccine: Drug information</a></li><li><a href=\"topic.htm?path=rabies-virus-vaccine-patient-drug-information\" class=\"drug drug_patient\">Rabies virus vaccine: Patient drug information</a></li></ul></div></div>","javascript":null}